Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
ARISTOTLE
About the Trial
The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial randomized 18,201 patients to apixaban 5 mg twice daily or warfarin. Apixaban reduced stroke or systemic embolism by 21 percent, major bleeding by 31 percent, and all cause mortality by 11 percent. It was the only DOAC trial to show superiority on all three key outcomes simultaneously. Lower rates of intracranial hemorrhage drove the benefit. Apixaban became one of the most widely prescribed DOACs. AVERROES had already shown apixaban superiority over aspirin when warfarin was unsuitable.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...